See the DrugPatentWatch profile for Xtandi
Xtandi (enzalutamide) received its initial U.S. Food and Drug Administration (FDA) approval on November 15, 2012 [1]. This approval was for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1].
When did Xtandi get approved for other uses?
Following its initial approval, Xtandi has received further FDA approvals for different stages of prostate cancer. It was approved for non-metastatic castration-resistant prostate cancer (nmCRPC) on February 17, 2018 [1]. Additionally, Xtandi gained approval for metastatic castration-sensitive prostate cancer (mCSPC) in August 2019 [1].
What is Xtandi's patent status?
The patent landscape for Xtandi is complex, with multiple patents covering the drug and its uses. Information regarding specific patent expiry dates and any associated litigation can be found on DrugPatentWatch.com [2].
How does Xtandi work?
Xtandi is an androgen receptor signaling inhibitor [1]. It works by blocking multiple steps in the androgen receptor signaling pathway [1]. This pathway is crucial for the growth and survival of prostate cancer cells [1].
What are the potential side effects of Xtandi?
Common side effects associated with Xtandi include fatigue, back pain, diarrhea, nausea, hot flush, and joint swelling or pain [1]. More serious side effects can also occur [1]. Patients and healthcare providers should discuss the full range of potential risks and benefits [1].